NRAS and metastatic melanoma: We next performed immunohistochemical analysis of biopsies from 54 patients with genetically diverse metastatic melanoma and confirmed high expression of BRD4 in NRASMut tumors; BRD4 levels were markedly higher than in tumors harboring mutant BRAF or wild‐type for BRAF and NRAS (WT) (Fig 1B and C).